tbuckley/cabot-search huggingface dataset:
Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis
Authors: Li Sun, Chao Huang, Miaolin Zhu, Shuwei Guo, Qiuzhi Gao, Qianqian Wang, Bin Chen, Rong Li, Yuanyuan Zhao, Mei Wang, Zhihong Chen, Bo Shen, Wei Zhu
Journal: Theranostics (2020)

Rationale: Mesenchymal stem cells (MSCs) have been the focus of many studies because of their abilities to modulate immune responses, angiogenesis, and promote tumor growth and metastasis. Our previous work showed that gastric cancer MSCs (GCMSCs) promoted immune escape by secreting of IL-8, which induced programmed cell death ligand 1 (PD-L1) expression in GC cells. Mounting evidence has revealed that PD-L1 expression is related to intrinsic tumor cell properties. Here, we investigated whether GCMSCs maintained a pool of cancer stem cells (CSCs) through PD-L1 signaling and the specific underlying molecular mechanism. Methods: Stem cell surface markers, aldehyde dehydrogenase (ALDH) activity, migration and sphere formation abilities were tested to evaluate the stemness of GC cells. PD-L1-expressing lentivirus and PD-L1 specific siRNA were used to analyze the effects of PD-L1 on GC cells stemness. Annexin V/PI double staining was used to assess apoptosis of GC cells induced by chemotherapy. Co-Immunoprecipitation (Co-IP) and Mass spectrometry were employed to determine the PD-L1 binding partner in GC cells. PD-L1Negative and PD-L1Positive cells were sorted by flow cytometry and used for limiting dilution assays to verify the effect of PD-L1 on tumorigenic ability in GC cells. Results: The results showed that GCMSCs enhanced the CSC-like properties of GC cells through PD-L1, which led to the resistance of GC cells to chemotherapy. PD-L1 associated with CTCF to contribute to the stemness and self-renewal of GC cells. In vivo, PD-L1Positive GC cells had greater stemness potential and tumorigenicity than PD-L1Negative GC cells. The results also indicated that GC cells were heterogeneous, and that PD-L1 in GC cells had different reactivity to GCMSCs. Conclusions: Overall, our data indicated that GCMSCs enriched CSC-like cells in GC cells, which gives a new insight into the mechanism of GCMSCs prompting GC progression and provides a potential combined therapeutic target.
A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies
Authors: Chi-Joan How, Siyang Ren, Jennifer Lombardi Story, Meghan Bergeron, Julia E. Foster, Philip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno R. Hock, Jenna A. Moran, Rupa Narayan, Donna S. Neuberg, Aura Y. Ramos, Tina T. Som, Megan Vartanian, Yi-Bin Chen, Gabriela S. Hobbs
Journal: Blood (2020)
Publisher Correction: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
Authors: Mitra K. Nadim, Lui G. Forni, Ravindra L. Mehta, Michael J. Connor, Kathleen D. Liu, Marlies Ostermann, Thomas Rimmelé, Alexander Zarbock, Samira Bell, Azra Bihorac, Vincenzo Cantaluppi, Eric Hoste, Faeq Husain-Syed, Michael J. Germain, Stuart L. Goldstein, Shruti Gupta, Michael Joannidis, Kianoush Kashani, Jay L. Koyner, Matthieu Legrand, Nuttha Lumlertgul, Sumit Mohan, Neesh Pannu, Zhiyong Peng, Xose L. Perez-Fernandez, Peter Pickkers, John Prowle, Thiago Reis, Nattachai Srisawat, Ashita Tolwani, Anitha Vijayan, Gianluca Villa, Li Yang, Claudio Ronco, John A. Kellum
Journal: Nature Reviews Nephrology (2020)

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Efficient Correction of HAX1 Mutations in Primary HSPCs of Severe Congenital Neutropenia Patients Using CRISPR/CAS9 GENE-Editing
Authors: Malte U Ritter, Benjamin Secker, Masoud Nasri, Maksim Klimiankou, Benjamin Dannenmann, Diana Amend, Jeremy Haaf, Perihan Mir, Regine Bernhard, Ingeborg Steiert, Cornelia Zeidler, Karl Welte, Julia Skokowa
Journal: Blood (2020)
Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)
Authors: Nicolas Gauthier, Juliette Soret-Dulphy, Lin-Pierre Zhao, Rafael Daltro De Oliveira, Clemence Marcault, Nathalie Parquet, Jean-Marc Zini, Delphine Rea, Emmanuel Raffoux, Bruno Cassinat, Stephane Giraudier, Jean-Jacques Kiladjian, Lina Benajiba
Journal: Blood (2020)
Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia
Authors: June Takeda, Kenichi Yoshida, Akinori Yoda, Lee-Yung Shih, Yasuhito Nannya, Yotaro Ochi, Ayana Kon, Kenichi Chiba, Yuichi Shiraishi, Yusuke Shiozawa, Tetsuichi Yoshizato, Cassandra M Kerr, Yasunobu Nagata, Toshiyuki Kitano, Akira Hangaishi, Ken Ishiyama, Hisashi Tsurumi, Yasushi Miyazaki, Nobuhiro Hiramoto, Takayuki Ishikawa, Masahiro Marshall Nakagawa, Akifumi Takaori-Kondo, Shigeru Chiba, Hideyuki Nakazawa, Ming-Chung Kuo, Keisuke Kataoka, Ryunosuke Saiki, Hiroko Tanaka, Kensuke Usuki, Shuichi Miyawaki, Satoru Miyano, Jaroslaw P. Maciejewski, Arnold Ganser, Michael Heuser, Felicitas Thol, Hideki Makishima, Seishi Ogawa
Journal: Blood (2020)
Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Authors: Junfang Yang, Pengfei Jiang, Xian Zhang, Jingjing Li, Yan Wu, Li Xu, Yunchao Su, Xiaona Hu, Xiaoyan Zhao, Qi Dong, Songbai Cai, Zhenguang Wang, Yuezhang Chen, Xun Ye, Jiaping He, Nanjing Lin, Wei Cao, Martina Sersch, Peihua Lu
Journal: Blood (2020)
Anterior Approach vs Conventional Hepatectomy for Resection of Colorectal Liver Metastasis
Authors: Nuh N. Rahbari, Emrullah Birgin, Ulrich Bork, Arianeb Mehrabi, Christoph Reißfelder, Jürgen Weitz
Journal: JAMA Surgery (2020)

Tumor relapse after partial hepatectomy for colorectal liver metastasis (CRLM) remains an unsolved issue. Intraoperative manipulation of the liver during conventional hepatectomy might enhance hematogenous tumor cell spread. The anterior approach is an alternative approach that may reduce intraoperative tumor cell dissemination.To determine the efficacy and safety of the anterior approach compared with conventional hepatectomy in patients undergoing resection for CRLM.This randomized clinical study evaluated the efficacy and safety of the anterior approach compared with conventional hepatectomy in adult patients with CRLM who were scheduled for hepatectomy from February 1, 2003, to March 31, 2012, at a tertiary-care hospital. A total of 80 patients with CRLM were randomized to the anterior approach and conventional hepatectomy groups in a 1:1 ratio. Bone marrow and blood samples were analyzed for disseminated tumor cells and circulating tumor cells (CTC) using cytokeratin 20 reverse transcriptase-polymerase chain reaction analysis. Data were analyzed from April 1 to December 1, 2018, using intention to treat.Anterior approach vs conventional hepatectomy.The primary end point was intraoperative CTC detection in central blood samples after liver resection. Secondary end points included postoperative morbidity, mortality, and long-term survival.Among the 80 patients included in the analysis (48 men [60%]; mean [SD] age, 61 [10] years), baseline characteristics, including preoperative CTC detection, were comparable between both groups. There was no statistically significant difference in intraoperative CTC detection between patients in the conventional hepatectomy (5 of 21 [24%]) and anterior approach (6 of 22 [27%]) groups (P = .54). Except for a longer operating time in the anterior approach group (mean [SD], 171 [53] vs 221 [53] minutes; P < .001), there were no significant differences in intraoperative and postoperative outcomes between both study groups. Although detection of CTC was associated with poor overall (median, 46 [95% CI, 40-52] vs 81 [95% CI, 54-107] months; P = .03) and disease-free (median, 40 [95% CI, 34-46] vs 60 [95% CI, 46-74] months; P = .04) survival, there was no significant difference in overall (median, 73 [95% CI, 42-104] vs 55 [95% CI, 35-75] months; P = .43) and disease-free (median, 48 [95% CI, 40-56] vs 40 [95% CI, 28-52] months; P = .88) survival between the conventional hepatectomy and anterior approach groups. Also, there was no significant difference in patterns of recurrence between both groups.This randomized clinical trial found that the anterior approach was not superior to conventional hepatectomy in reducing intraoperative tumor cell dissemination in patients undergoing resection of CRLM.isrctn.org Identifier: ISRCTN45066244.
Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant
Authors: Audrey M. Sigmund, Qiuhong Zhao, Justin Jiang, Patrick Elder, Don M. Benson, Ashley Rosko, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Basem M. William, Alice S. Mims, Hannah Choe, Karilyn Larkin, Jonathan E Brammer, Sarah A Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera, Nidhi Sharma
Journal: Blood (2020)
i-CONTENT tool for assessing therapeutic quality of exercise programs employed in randomised clinical trials
Authors: Thomas J Hoogeboom, Martijn C Kousemaker, Nico LU van Meeteren, Tracey Howe, Kari Bo, Peter Tugwell, Manuela Ferreira, Rob A de Bie, Cornelia HM van den Ende, Jennifer E Stevens-Lapsley
Journal: British Journal of Sports Medicine (2020)

Objective When appraising the quality of randomised clinical trial (RCTs) on the merits of exercise therapy, we typically limit our assessment to the quality of the methods. However, heterogeneity across studies can also be caused by differences in the quality of the exercise interventions (ie, ‘the potential effectiveness of a specific intervention given the potential target group of patients’)—a challenging concept to assess. We propose an internationally developed, consensus-based tool that aims to assess the quality of exercise therapy programmes studied in RCTs: the international Consensus on Therapeutic Exercise aNd Training (i-CONTENT) tool. Methods Forty-nine experts (from 12 different countries) in the field of physical and exercise therapy participated in a four-stage Delphi approach to develop the i-CONTENT tool: (1) item generation (Delphi round 1), (2) item selection (Delphi rounds 2 and 3), (3) item specification (focus group discussion) and (4) tool development and refinement (working group discussion and piloting). Results Out of the 61 items generated in the first Delphi round, consensus was reached on 17 items, resulting in seven final items that form the i-CONTENT tool: (1) patient selection; (2) qualified supervisor; (3) type and timing of outcome assessment; (4) dosage parameters (frequency, intensity, time); (5) type of exercise; (6) safety of the exercise programme and (7) adherence to the exercise programme. Conclusion The i-CONTENT-tool is a step towards transparent assessment of the quality of exercise therapy programmes studied in RCTs, and ultimately, towards the development of future, higher quality, exercise interventions.
Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models
Authors: Weiguo Zhang, Kyung Hee Chang, Mahesh Basyal, Yannan Jia, Lauren B Ostermann, William E. Fogler, John L. Magnani, M Anna Zal, Tomasz Zal, Michael Andreeff
Journal: Blood (2020)
Allogeneic Stem Cell Transplantation in a Large Urban Cohort of North-American Adult T-Cell Leukemia/Lymphoma
Authors: Astha Thakkar, Diego Adrianzen Herrera, Shafia Rahman, Zhu Cui, Angelica D'Aiello, Amanda Lombardo, Fariha Khatun, Jennat Mustafa, Kailyn Gillick, Felisha Joseph, Anjali Naik, Latoya Townsend Nugent, Nicole Chambers, Rosmi Mathew, Michelly Abreu, Richard Elkind, Henrietta Noicely, Ruby Yusay, Carlo Palesi, Randin Nelson, Donika Binakaj, Ulrich G. Steidl, Olga Derman, Kira Gritsman, Noah Kornblum, Ioannis Mantzaris, Aditi Shastri, Mendel Goldfinger, Lizamarie Bachier-Rodriguez, B. Hilda Ye, Amit Verma, Ira Braunschweig, Murali Janakiram, R. Alejandro Sica
Journal: Blood (2020)
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
Authors: Arleigh McCurdy, Christopher P. Venner, Martha L Louzada, Richard LeBlanc, Michael Sebag, Kevin W Song, Victor Jimenez-Zepeda, Rami Kotb, Esther Masih-Khan, Eshetu G Atenafu, Hira S Mian, Darrell J White, Julie Stakiw, Muhammad Aslam, Anthony Reiman, Engin Gul, Donna E. Reece
Journal: Blood (2020)
Genome Size Evolution Mediated by <i>Gypsy</i> Retrotransposons in Brassicaceae
Authors: Shi-Jian Zhang, Lei Liu, Ruolin Yang, Xiangfeng Wang
Journal: Genomics Proteomics & Bioinformatics (2020)

The dynamic activity of transposable elements (TEs) contributes to the vast diversity of genome size and architecture among plants. Here, we examined the genomic distribution and transposition activity of long terminal repeat retrotransposons (LTR-RTs) in Arabidopsis thaliana (Ath) and three of its relatives, Arabidopsis lyrata (Aly), Eutrema salsugineum (Esa), and Schrenkiella parvula (Spa), in Brassicaceae. Our analyses revealed the distinct evolutionary dynamics of Gypsyretrotransposons, which reflects the different patterns of genome size changes of the four species over the past million years. The rate of Gypsy transposition in Aly is approximately five times more rapid than that of Ath and Esa, suggesting an expanding Aly genome. Gypsy insertions in Esa are strictly confined to pericentromeric heterochromatin and associated with dramatic centromere expansion. In contrast, Gypsy insertions in Spa have been largely suppressed over the last million years, likely as a result of a combination of an inherent molecular mechanism of preferential DNA removal and purifying selection at Gypsy elements. Additionally, species-specific clades of Gypsy elements shaped the distinct genome architectures of Aly and Esa.
Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes
Authors: Matilde Y Follo, Sara Mongiorgi, Alessia De Stefano, Valentina Indio, Annalisa Astolfi, Andrea Pellagatti, Stefano Ratti, Miriam Fogli, Sarah Parisi, Andrea Pession, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Carlo Finelli
Journal: Blood (2020)
PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
Authors: Olivier Casasnovas, Judith Racape, Julie Dechene, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, Aspasia Stamatoulas Bastard, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, Marc André, Alina Berriolo-Riedinger, Veronique Edeline, Clémentine Joubert, Michel Meignan, Isabelle Demeestere
Journal: Blood (2020)
Abstract PO-125: Targeting histone methylation to overrule transcriptionally driven drug resistance in myeloid leukemia
Authors: Noortje van Gils, Han J.M.P. Verhagen, Tània Martiáñez, Fedor Denkers, Eline Vermue, Arjo Rutten, Tamás Csikós, Meyrem Çil, Marjon Al, Frank van Gemert, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Renee X. Menezes, Linda Smit
Journal: Cancer Research (2020)

Abstract Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been the first-line therapeutic to treat acute myeloid leukemia (AML). Although this treatment induces complete remissions (CR) in the majority of patients, many face a relapse. Relapse is caused by the survival of chemotherapy-resistant leukemia cells (minimal residual disease, MRD), that may have acquired drug resistance by non-genetic mechanisms. Persistence of MRD is driven by intra-leukemic heterogeneity and plasticity in response to therapy. Leukemia cells within MRD capable of initiating relapse are thought to have stem cell features and are therefore named “leukemic stem cells” (LSCs). In this study, we demonstrated that the anthracycline doxorubicin epigenetically reprograms leukemia cells by inducing tri-methylation of histone 3 lysine 27 (H3K27) and H3K4. Moreover, to understand chemotherapy resistance at the single-cell level and to study intra-leukemia heterogeneity with respect to anthracycline sensitivity, we seeded K562 myeloid leukemia cells in 480 wells, each containing 10.000 cells, and treated the cells with increasing concentrations of doxorubicin. Using this approach, a subpopulation of reversible anthracycline-tolerant cells (ATCs) was identified within the doxorubicin-sensitive leukemia cell population, which lacked upregulation of H3K27me3 or H3K4me3 and exhibited epigenetically regulated expression of stem cell features similar to leukemic stem cells (LSCs). These ATCs have a distinct transcriptional landscape from the leukemia bulk and could be eradicated by the KDM6 inhibitor GSK-J4. In primary human AML, GSK-J4 treatment could eliminate AML blasts and LSCs at diagnosis but importantly it could significantly reduce chemotherapy resistant AML patient cell load (MRD) and survival of LSCs residing within MRD, ex vivo and in vivo. An efficient response to GSK-J4 was associated with upregulation of H3K27 and/or H3K4 methylation, and downregulation of STAT5B. Together, our results reveal plasticity of anthracycline resistance in AML cells and highlight the potential of epigenetic-based therapeutics to target chemotherapy-resistant AML cells. Citation Format: Noortje van Gils, Han J.M.P. Verhagen, Tània Martiáñez, Fedor Denkers, Eline Vermue, Arjo Rutten, Tamás Csikós, Meyrem Çil, Marjon Al, Frank van Gemert, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Renee X. Menezes, Linda Smit. Targeting histone methylation to overrule transcriptionally driven drug resistance in myeloid leukemia [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-125.
A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab
Authors: Koji Sasaki, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Partow Kebriaei, Xuelin Huang, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Koichi Takahashi, Hind Rafei, Sa A Wang, Joseph D. Khoury, Jeffrey L. Jorgensen, Maria Khouri, Jovitta Jacob, Rebecca Garris, Susan M. O'Brien, Elias Jabbour
Journal: Blood (2020)
Injury characteristics in male youth athletics: a five-season prospective study in a full-time sports academy
Authors: Daniel Martínez-Silván, Eirik Halvorsen Wik, Juan Manuel Alonso, Evan Jeanguyot, Benjamin Salcinovic, Amanda Johnson, Marco Cardinale
Journal: British Journal of Sports Medicine (2020)

To describe the injury characteristics of male youth athletes exposed to year-round athletics programmes.Injury surveillance data were prospectively collected by medical staff in a cohort of youth athletics athletes participating in a full-time sports academy from 2014-2015 to 2018-2019. Time-loss injuries (>1 day) were recorded following consensus procedures for athletics. Athletes were clustered into five event groups (sprints, jumps, endurance, throws and non-specialised) and the number of completed training and competition sessions (athletics exposures (AE)) were calculated for each athlete per completed season (one athlete season). Injury characteristics were reported overall and by event groups as injury incidence (injuries per 1000 AE) and injury burden (days lost per 1000 AE).One-hundred and seventy-eight boys (14.9±1.8 years old) completed 391 athlete seasons, sustaining 290 injuries. The overall incidence was 4.0 injuries per 1000 AE and the overall burden was 79.1 days lost per 1000 AE. The thigh was the most common injury location (19%). Muscle strains (0.7 injuries per 1000 AE) and bone stress injuries (0.5 injuries per 1000 AE) presented the highest incidence and stress fractures the highest burden (17.6 days lost per 1000 AE). The most burdensome injury types by event group were: bone stress injuries for endurance, hamstring strains for sprints, stress fractures for jumps, lesion of meniscus/cartilage for throws and growth plate injuries for non-specialised athletes.Acute muscle strains, stress fractures and bone stress injuries were identified as the main injury concerns in this cohort of young male athletics athletes. The injury characteristics differed between event groups.
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance
Authors: Hardeep Singh Tuli, Sonam Mittal, Diwakar Aggarwal, Gaurav Parashar, Nidarshana Chaturvedi Parashar, Sushil Kumar Upadhyay, Tushar Singh Barwal, Aklank Jain, Ginpreet Kaur, Raj Savla, Katrin Sak, Manoj Kumar, Mehmet Varol, Ashif Iqubal, Anil Kumar Sharma
Journal: Seminars in Cancer Biology (2020)
<i>In situ</i> tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor
Authors: Chen Chen, Shengchang Zhang, Rui Zhang, Peng Sun, Chongdeng Shi, Mohnad Abdalla, Anning Li, Jiawen Xu, Wei Du, Jing Zhang, Ying Liu, Chunwei Tang, Zhenmei Yang, Xinyi Jiang
Journal: Theranostics (2020)

Rationale: Vascular abnormality stemming from the hypoxia-driven elevation of proangiogenic factors is a hallmark for many solid malignant tumors, including colorectal cancer (CRC) and its liver metastasis. We report a hypoxia-triggered liposome-supported metal-polyphenol-gene bio-nanoreactor to tune the proangiogenic factor-mediated immunotolerance and synergize the elicited tumoricidal immunity for CRC treatment. Methods: With the aid of polyphenol gallic acid, Cu2+ ion-based intracellular bio-nanoreactor was synthesized for the delivery of small interfering RNA targeting vascular endothelial growth factor and then cloaked with a hybrid liposomal membrane that harbored a hypoxia-responsive azobenzene derivative. In hypoxic tumor, the liposomal shell disintegrated, and a shrunk-size bio-nanoreactor was burst released. Intracellularly, Cu2+ from the bio-nanoreactor catalyzed a Fenton-like reaction with glutathione, which efficiently converted H2O2 to •OH and enabled a chemodynamic therapy (CDT) in tumor sites. With the alleviation of proangiogenic factor-mediated immunotolerance and high production of CDT-induced tumor-associated antigens, robust tumoricidal immunity was co-stimulated. Results: With colorectal tumor and its liver metastasis models, we determined the underlying mechanism of proangiogenic factor-mediated immunotolerance and highlighted that the liposomal bio-nanoreactor could create positive feedback among the critical players in the vascular endothelium and synergize the elicited tumoricidal immunity. Conclusion: Our work provides an alternative strategy for exerting efficient tumoricidal immunity in the proangiogenic factor-upregulated subpopulation of CRC patients and may have a wide-ranging impact on cancer immune-anti-angiogenic complementary therapy in clinics.